Product Name: CD79a Antibody [JCB117]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC, WB
Applications: Flow Cytometry: 0.5-1 ug/million cellsIF: 0.5-1 ug/mlIHC (FFPE): 0.5-1 ug/ml for 30 minutes at RT (1)Prediluted format : incubate for 30 min at RT (2)The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD79a antibody to be titered up or down for optimal performance.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Amino acids 202-216 (GTYQDVGSLNIADVQ) were used as the immunogen for this CD79a antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 440-17-5
Product: Trifluoperazine (dihydrochloride)
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: B-cell antigen receptor complex-associated protein alpha chain, Ig-alpha, MB-1 membrane glycoprotein, Membrane-bound immunoglobulin-associated protein, Surface IgM-associated protein, CD79a, CD79A, IGA, MB1
Accession NO.:
Protein Ino:
Official Symbol: CD79A
Geneid: 973
Background: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B-cell Ag receptor. CD79a first appears at pre B-cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. It is found in the majority of acute leukemias of B-cell precursors, lines and lymphomas, and in some myelomas. It is not present in myeloid or Tcell lines. CD79a antibody is generally used to complement CD20 mAb, especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This CD79a antibody will stain many of the same lymphomas as CD20 mAb, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 mAb. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
PubMed ID:http://aac.asm.org/content/35/3/594.abstract
